CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 97
- Registration Number
- NCT03566017
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Renal Disease Research Institute, LLC - Dallas, Dallas, Texas, United States
🇺🇸O+O Alpan LLC, Fairfax, Virginia, United States
The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 158
- Registration Number
- NCT03558373
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹A.O.U. Consorziale Policlinico, Bari, Italy
🇮🇹A.O.U. Policlinico S.Orsola Malpighi, Bologna, Italy
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
- Conditions
- Interventions
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 494
- Registration Number
- NCT03453112
- Locations
- 🇨🇳
Chiesi Clinical Trial site 15670, Guizhou, China
🇨🇳Chiesi Clinical Trial site 15641, Hefei, Anhui, China
🇨🇳Chiesi clinical Trial site 15656, Guangzhou, Guangdong, China
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 118
- Registration Number
- NCT03378648
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Functional Respiratory Imaging Study (FRI)
- Conditions
- Interventions
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT03268226
- Locations
- 🇭🇺
National Koranyi Institute for TB and Pulmonology, Budapest, Hungary
🇧🇪Heilige Familie AZ, Reet, Belgium
🇧🇪SGS CPU Antwerpen, Antwerpen, Belgium
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
- Conditions
- Interventions
- Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 166
- Registration Number
- NCT03235986
- Locations
- 🇮🇹
Prof.Carlo Dani, Coordinating Investigator - Careggi Hospital, Florence (Italy), Firenze, Italy
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
- Conditions
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 990
- Registration Number
- NCT03197818
- Locations
- 🇨🇳
Chiesi Clinical Trial Site 158001, Keelung, Keelung Municipality, Taiwan
🇨🇳Chiesi Clinical Trial Site 158006, Kaohsiung, Taiwan
🇨🇳Chiesi Clinical Trial Site 158011, Taipei, Taiwan
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 65
- Registration Number
- NCT03108534
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧University of Dundee, Dundee, United Kingdom
🇬🇧Hammersmith Medicines Research, London, United Kingdom
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
- Conditions
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 67
- Registration Number
- NCT03086460
- Locations
- 🇺🇸
Chiesi Investigational Site, Richland, Washington, United States
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 733
- Registration Number
- NCT03084796
- Locations
- 🇺🇸
Clinical Research Solutions, Dayton, Ohio, United States
🇺🇸Chiesi Investigational Site, Tacoma, Washington, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States